Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Nicox SA (COX) EUR1

Sell:€3.99 Buy:€4.00 Change: €0.045 (1.14%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:€3.99
Buy:€4.00
Change: €0.045 (1.14%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:€3.99
Buy:€4.00
Change: €0.045 (1.14%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Nicox SA is a France-based international ophthalmic company. It is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The Company has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). It has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.

Contact details

Address:
Drakkar 2 - Batiment D
2405 route des Dolines
CS 10313 Sophia Antipolis
VALBONNE
06560
France
Telephone:
+33 (4) 97245300
Website:
www.nicox.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
COX
ISIN:
FR0013018124
Market cap:
€131.43 million
Shares in issue:
29.91 million
Sector:
Biotechnology
Exchange:
Euronext Paris
Country:
France
Currency:
Euro
Indices:
n/a

Key personnel

  • Michele Garufi
    Chairman of the Board and Chief Executive Officer, Member of the Management Committee
  • Sandrine Gestin
    Finance Director, Member of the Management Committee
  • Michael Bergamini
    Executive Vice President, Chief Scientific Officer, Member of the Management Committee
  • Gavin Spencer
    Executive Vice President & Chief Business Officer, Member of the Management Committee
  • Tomas Navratil
    Vice President, Head of Development, Member of the Management Committee
  • Emmanuelle Pierry
    Senior Director of Legal Affairs, Member of the Management Committee

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.